vs
Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
APOGEE ENTERPRISES, INC. is the larger business by last-quarter revenue ($351.4M vs $196.9M, roughly 1.8× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 1.6%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 2.9%).
Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
APOG vs PCRX — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $351.4M | $196.9M |
| Net Profit | $16.6M | — |
| Gross Margin | 22.4% | 79.5% |
| Operating Margin | 7.3% | 1.2% |
| Net Margin | 4.7% | — |
| Revenue YoY | 1.6% | 5.1% |
| Net Profit YoY | 568.8% | — |
| EPS (diluted) | $0.78 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | $196.9M | ||
| Q3 25 | $358.2M | $179.5M | ||
| Q2 25 | $346.6M | $181.1M | ||
| Q1 25 | $345.7M | $168.9M | ||
| Q4 24 | $341.3M | $187.3M | ||
| Q3 24 | $342.4M | $168.6M | ||
| Q2 24 | $331.5M | $178.0M |
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | — | ||
| Q3 25 | $23.6M | $5.4M | ||
| Q2 25 | $-2.7M | $-4.8M | ||
| Q1 25 | $2.5M | $4.8M | ||
| Q4 24 | $21.0M | — | ||
| Q3 24 | $30.6M | $-143.5M | ||
| Q2 24 | $31.0M | $18.9M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 79.5% | ||
| Q3 25 | 23.1% | 80.9% | ||
| Q2 25 | 21.7% | 77.4% | ||
| Q1 25 | 21.6% | 79.7% | ||
| Q4 24 | 26.1% | 78.7% | ||
| Q3 24 | 28.4% | 76.9% | ||
| Q2 24 | 29.8% | 75.1% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | 1.2% | ||
| Q3 25 | 7.5% | 3.5% | ||
| Q2 25 | 2.0% | 4.7% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 8.4% | 13.2% | ||
| Q3 24 | 12.3% | -82.8% | ||
| Q2 24 | 12.5% | 15.9% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 6.6% | 3.0% | ||
| Q2 25 | -0.8% | -2.7% | ||
| Q1 25 | 0.7% | 2.8% | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 8.9% | -85.1% | ||
| Q2 24 | 9.4% | 10.6% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | $0.05 | ||
| Q3 25 | $1.10 | $0.12 | ||
| Q2 25 | $-0.13 | $-0.11 | ||
| Q1 25 | $0.12 | $0.10 | ||
| Q4 24 | $0.96 | $0.38 | ||
| Q3 24 | $1.40 | $-3.11 | ||
| Q2 24 | $1.41 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.5M | $238.4M |
| Total DebtLower is stronger | $232.3M | $372.2M |
| Stockholders' EquityBook value | $511.8M | $693.1M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.45× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | $238.4M | ||
| Q3 25 | $39.5M | $246.3M | ||
| Q2 25 | $32.8M | $445.9M | ||
| Q1 25 | $41.4M | $493.6M | ||
| Q4 24 | $43.9M | $484.6M | ||
| Q3 24 | $51.0M | $453.8M | ||
| Q2 24 | $30.4M | $404.2M |
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | $285.0M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | $693.1M | ||
| Q3 25 | $500.2M | $727.2M | ||
| Q2 25 | $481.8M | $757.8M | ||
| Q1 25 | $487.9M | $798.5M | ||
| Q4 24 | $522.1M | $778.3M | ||
| Q3 24 | $506.4M | $749.6M | ||
| Q2 24 | $480.0M | $879.3M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $917.1M | $1.5B | ||
| Q2 24 | $889.0M | $1.6B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 0.58× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $122.5M | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | 7.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 7.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $43.7M | ||
| Q3 25 | $57.1M | $60.8M | ||
| Q2 25 | $-19.8M | $12.0M | ||
| Q1 25 | $30.0M | $35.5M | ||
| Q4 24 | $31.0M | $33.1M | ||
| Q3 24 | $58.7M | $53.9M | ||
| Q2 24 | $5.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $43.5M | ||
| Q3 25 | $52.4M | $57.0M | ||
| Q2 25 | $-26.9M | $9.3M | ||
| Q1 25 | $19.1M | $26.9M | ||
| Q4 24 | $22.0M | $31.0M | ||
| Q3 24 | $50.2M | $49.8M | ||
| Q2 24 | $-1.8M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 22.1% | ||
| Q3 25 | 14.6% | 31.7% | ||
| Q2 25 | -7.8% | 5.1% | ||
| Q1 25 | 5.5% | 15.9% | ||
| Q4 24 | 6.4% | 16.6% | ||
| Q3 24 | 14.7% | 29.6% | ||
| Q2 24 | -0.5% | 29.0% |
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 2.1% | 1.5% | ||
| Q1 25 | 3.2% | 5.1% | ||
| Q4 24 | 2.6% | 1.1% | ||
| Q3 24 | 2.5% | 2.4% | ||
| Q2 24 | 2.2% | 0.9% |
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.08× | 7.37× | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
